Lykos Therapeutics Announces Complete Response Letter for Midomafetamine Capsules for PTSD

Lykos Therapeutics received a complete response letter from the FDA for midomafetamine capsules for PTSD, requesting an additional Phase 3 trial. The company plans to meet with the FDA to discuss resubmission and address concerns raised during the Advisory Committee meeting.